New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer

Table 1 Results from studies with tyrosine kinase inhibitor’s in 1^st line treatment of non-small cell lung cancer

Study and ref.	n	Treatment	RR (%)	P	PFS (mo)	HR	OS (mo)	HR
						P		P
IPASS[9]	437	Gefitinib/	71.2/47.3	0.01	9.5/5.3	0.48	21.6/21.9	0.99
		Carboplatin + Paclitaxel				(< 0.001)
WJTOG[10]	177	Gefitinib/	62.1/32.2	0.01	9.2/6.3	0.49	30.9/NA	1.64
		Cisplatin + Docetaxel				-0.001
NEJ[11]	230	Gefitinib/	73.7/30.7	0.01	10.8/5.4	0.3	30.5/23.6	NA
		Carboplatin + Paclitaxel				-0.001
OPTIMAL[12]	154	Erlotinib/	83/36	0.01	13.1/4.6	0.16	22.6/28.8	1.06
		Carboplatin + Gemcitabin				-0.001
EURTAC[13]	173	Erlotinib/	58/15	0.01	9.7/5.2	0.37	19.3/19.5	1.04
		Platin doublet				-0.001
LUX-LUNG3[14]	345	Afatinib/	56/23	0.01	11.1/6.9	0.58	NA	1.12
		Cisplatin + pemetrexed				-0.001

NA: Not available; RR: Response rate; PFS: Progression free survival; HR: Hazard ratio; OS: Overall survival.

Table 2 Evaluation of outcome of tyrosine kinase inhibitor’s treatment according to epidermal growth factor receptor mutations or epidermal growth factor receptor wild-type[20,29]

EGFR mutations		RR %	PFS (mo)	OS (mo)
Most common	Del exon 9	74	8.5	19.6
	L858R exon 21
Less frequent	G719X exon18	53.3	8.1	16.4
	L861Q exon 21	60	6	15.2
Uncommon	V769M	20	1.6	11.1
	A871E
EGFR wild-type		16.5	2	10.4

EGFR: Epidermal growth factor receptor; RR: Response rate; PFS: Progression free survival; OS: Overall survival.

Table 3 Phase I clinical studies of third generation epidermal growth factor receptor- tyrosine kinase inhibitors[26-28]

Study and ref.	n	EGFR mutations	ORR (%)	ORR in EGFRT790M (%)	ORR in non EGFRT790M (%)
AZD9291[26]	232	exon 19del	53	64	22
		L858R
		T790M
CO-1686[27]	72	exon 19del	NA	58	NA
		L858R
		T790M
HM61713[28]	83	T790M	21.7	29.2	NA

EGFR: Epidermal growth factor receptor; NA: Not available.